1496-40-8|2-(Piperidin-1-yl)-5-(trifluoromethyl)aniline| Ambeed

Structure of 1496-40-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 1496-40-8 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 1496-40-8 ]

CAS No. :	1496-40-8
Formula :	C₁₂H₁₅F₃N₂
M.W :	244.26
SMILES Code :	NC1=CC(C(F)(F)F)=CC=C1N2CCCCC2
MDL No. :	MFCD00042161
InChI Key :	BERRRZOJDANPHE-UHFFFAOYSA-N
Pubchem ID :	694756

Safety of [ 1496-40-8 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Application In Synthesis of [ 1496-40-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 1496-40-8 ]

[ 1496-40-8 ] Synthesis Path-Downstream 1~35

2
[ 1019327-29-7 ]
[ 1496-40-8 ]
[ 913067-83-1 ]

References: [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 5671 - 5686.

3
[ 186584-73-6 ]
[ 1496-40-8 ]
[ 926036-43-3 ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 627 - 640.

4
[ 926277-91-0 ]
[ 1496-40-8 ]
4-methyl-N-(2-(1-piperidinyl)-5-(trifluoromethyl)phenyl)-3-((3-(4-pyrimidinyl)-2-pyridinyl)oxy)benzamide [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 611 - 626.

5
[ 870221-16-2 ]
[ 1496-40-8 ]
4-methyl-N-(2-(1-piperidinyl)-5-(trifluoromethyl)phenyl)-3-((3-(4-pyrimidinyl)-2-pyridinyl)amino)benzamide [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 611 - 626.

6
[ 926277-89-6 ]
[ 1496-40-8 ]
4-methyl-3-((3-(2-(methylamino)-4-pyrimidinyl)-2-pyridinyl)oxy)-N-(2-(1-piperidinyl)-5-(trifluoromethyl)phenyl)benzamide [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 611 - 626.

7
2-fluoro-5-(3-(2-(methylamino)pyrimidin-4-yl)pyridin-2-yloxy)benzoic acid [ No CAS ]
[ 1496-40-8 ]
2-fluoro-5-[3-(2-methylamino-pyrimidin-4-yl)-pyridin-2-yloxy]-N-(2-piperidin-1-yl-5-trifluoromethyl-phenyl)-benzamide [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 611 - 626.

8
[ 1496-40-8 ]
[ 1711-10-0 ]
[ 688033-18-3 ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 627 - 640.

9
[ 1496-40-8 ]
[ 52107-98-9 ]
[ 926036-42-2 ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 627 - 640.

10
[ 333736-95-1 ]
[ 1496-40-8 ]
[ 586-30-1 ]
[ 74-89-5 ]
4-methyl-3-[4-(2-methylamino-pyridin-3-yl)-[1,3,5]triazin-2-yloxy]-N-(2-piperidin-1-yl-5-trifluoromethyl-phenyl)-benzamide [ No CAS ]
4-methyl-3-[3-(4-methylamino-[1,3,5]triazin-2-yl)-pyridin-2-yloxy]-N-(2-piperidin-1-yl-5-trifluoromethyl-phenyl)-benzamide [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 611 - 626.

11
[ 333736-95-1 ]
[ 1496-40-8 ]
[ 74-89-5 ]
[ 51446-30-1 ]
2-fluoro-5-[4-(2-methylamino-pyridin-3-yl)-[1,3,5]triazin-2-yloxy]-N-(2-piperidin-1-yl-5-trifluoromethyl-phenyl)-benzamide [ No CAS ]
2-fluoro-5-[3-(4-methylamino-[1,3,5]triazin-2-yl)-pyridin-2-yloxy]-N-(2-piperidin-1-yl-5-trifluoromethyl-phenyl)-benzamide [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 611 - 626.

12
[ 1692-79-1 ]
[ 1496-40-8 ]

Yield	Reaction Conditions	Operation in experiment
90.4%		Concentrated hydrochloric acid (2.00 ml, 24.0 mmol) and anhydrous tin dichloride (2.50 g, 13.1 mmol) were sequentially added at 0C to a methanol (10 ml) solution containing 1-[2-nitro-4-(trifluoromethyl)phenyl]piperidine (559 mg, 2.03 mmol), obtained as described in Referential Example 1-1A. The resulting mixture was warmed to room temperature and then stirred for 17.5 hours. A saturated aqueous solution of sodium bicarbonate was added to the mixture. The resulting mixture was extracted three times with ethyl acetate. The obtained organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (50 g, hexane/ethyl acetate = 14/1)). Thus, 2-(1-piperidinyl)-5-(trifluoromethyl)aniline (448 mg, 1.83 mmol, 90.4%) was yielded as a pale yellow solid. The results of TLC and 1H NMR (CDCl3, 400 MHz) are as follows: TLC Rf 0.30(hexane/acetone = 18/1); 1H NMR (CDCl3, 400 MHz) delta 1.59-1.60 (m, 2H, CH2), 1.71 (tt, 4H, J = 5.4, 5.4 Hz, 2CH2), 2.85 (brs, 4H, 2CH2), 4.09 (brs, 2H, NH2), 6.92 (d, 1H, J = 1.9 Hz, aromatic), 6.97 (dd, 1H, J = 1.9, 8.4 Hz, aromatic), 7.01 (d, 1H, J = 8.4 Hz, aromatic).
83.0%		Concentrated hydrochloric acid (12.2 ml, 146 mmol) and anhydrous tin dichloride (12.7 g, 67.2 mmol) were sequentially added at 0C to a dichloromethane solution (10 ml) of 1-[2-nitro-4-(trifluoromethyl)phenyl]piperidine (6.13 g, 22.4 mmol), obtained as described in Referential Example 1-1B. The resulting mixture was stirred for seven hours. Water was added to the mixture, and the resulting mixture was extracted three times with ethyl acetate. The obtained organic layer was washed with a saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (200 g, hexane/ethyl acetate = 15/1). Thus, 2-(1-piperidinyl)-5-(trifluoromethyl)aniline (4.55 g, 83.0%) was yielded as a pale yellow solid.
83.0%	With hydrogenchloride; tin dichloride; In dichloromethane; water;	[Reference example 1-2B] Concentrated hydrochloric acid (12.2 mL, 146 mmol) and anhydrous tin dichloride (12.7 g, 67.2 mmol) were added sequentially at 0C to a dichloromethane (10 mL) solution of 1-[2-nitro-4-(trifluoromethyl)phenyl]piperidine (6.13 g, 22.4 mmol) obtained in Reference example 1-1B. The mixture was stirred for 7 hours. Water was added to the mixture and then the mixture was subjected to extraction with ethyl acetate (x3). The thus obtained organic layer was washed with saturated sodium chloride solution, dried using anhydrous sodium sulfate, filtered, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (200 g, hexane/ethyl acetate = 15/1), so that 2-(1-piperidinyl)-5-(trifluoromethyl)aniline (4.55 g, 83.0%) was obtained as light yellow solid.

78%

With hydrogenchloride; tin(ll) chloride; In methanol; at 0 - 20℃; for 42h;

A 50 mLround bottom flask initially placed in an ice bath was charged with10.8 mL (129.6 mmol) of concentrated hydrocloric acid, 6.71 g(35.4 mmol) of tin(II) chloride, 20.0 mL of methanol, and 1.50 g(5.47 mmol) of 1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine(2). The ice bath was removed and the resulting mixture wascontinuously stirred at room temperature for 42 h. After this time,sodium hydroxide solution was added to the mixture until pH wasapproximately equal to 10. Then, the mixture was transferred to aseparatory funnel and extracted with ethyl acetate (4 x 80.0 mL).The organic extracts were combined and the resulting mixture waswashed with brine, dried under sodium sulphate, filtered andconcentrated under reduced pressure. The residue was purified bysilica gel column chromatography eluted with hexane-ethyl acetate(11:1 v/v). The compound 8 was obtained as a white solid in 78%yield (1.34 g, 5.49 mmol). TLC Rf = 0.48 (hexane-ethyl acetate 11:1 v/v). mp 50.0-50.5 C.IR (ATR, cm-1) numax: 3452, 3355, 2950, 2865, 2805, 1611, 1589, 1512,1469,1439,1379,1328,1288,1256,1227,1205,1160,1104,1064, 936,892, 860, 810, 745, 722, 663, 643. 1H NMR (300 MHz, CDCl3) delta:1.60-1.75 (m, 6H), 2.88 (brs, 4H), 4.11 (brs, 2H, NH2), 6.93-7.03 (m,3H). 13C NMR (75 MHz, CDCl3) delta: 24.4, 26.8, 52.4, 111.5 (q, J C-F = 3.5 Hz), 115.5 (q, J C-F = 4.1 Hz), 119.7, 124.7 (q, J C-F = 270.0 Hz), 126.1 (q, J C-F = 31.9 Hz), 141.7, 143.4. HRMS (M + H+): Calculated forC12H16F3N2, 245.1266; found: 245.1182.

References: [1]Patent: EP1712242,2006,A1 .Location in patent: Page/Page column 18; 30.
[2]Patent: EP1712242,2006,A1 .Location in patent: Page/Page column 18; 31.
[3]Patent: EP2279750,2011,A1 .
[4]European Journal of Medicinal Chemistry,2017,vol. 134,p. 97 - 109.
[5]Journal of Medicinal Chemistry,2007,vol. 50,p. 627 - 640.
[6]Journal of Medicinal Chemistry,2020,vol. 63,p. 103 - 121.

13
[ 110-89-4 ]
trityl thiosemicarbazide resin [ No CAS ]
[ 1496-40-8 ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 627 - 640.

14
[ 1496-40-8 ]
3-ethynyl-N-(2-piperidin-1-yl-5-trifluoromethyl-phenyl)-benzamide [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 627 - 640.

15
[ 1496-40-8 ]
5-ethynyl-2-fluoro-N-(2-piperidin-1-yl-5-trifluoromethyl-phenyl)-benzamide [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 627 - 640.

16
[ 1496-40-8 ]
3-ethynyl-4-methyl-N-(2-piperidin-1-yl-5-trifluoromethyl-phenyl)-benzamide [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 627 - 640.

17
[ 1496-40-8 ]
3-(2-amino-pyrimidin-5-ylethynyl)-N-(2-piperidin-1-yl-5-trifluoromethyl-phenyl)-benzamide [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 627 - 640.

18
[ 1496-40-8 ]
3-(2-amino-pyrimidin-5-ylethynyl)-4-methyl-N-(2-piperidin-1-yl-5-trifluoromethyl-phenyl)-benzamide [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 627 - 640.

19
[ 1496-40-8 ]
5-(2-(2-aminopyrimidin-5-yl)ethynyl)-2-methoxy-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)benzamide [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 627 - 640.

20
[ 1496-40-8 ]
[ 884602-75-9 ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 627 - 640.

21
[ 367-86-2 ]
[ 1496-40-8 ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 627 - 640.
[2]European Journal of Medicinal Chemistry,2017,vol. 134,p. 97 - 109.
[3]Journal of Medicinal Chemistry,2020,vol. 63,p. 103 - 121.

22
[ 1496-40-8 ]
[ 122-04-3 ]
N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]-4-nitrobenzamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
56.3%	With triethylamine; In dichloromethane; at 0 - 20℃; for 60h;	4-Nitrobenzoyl chloride (64.2 mg, 0.345 mmol, commercially available product) and triethylamine (120 mul, 0.859 mmol) were sequentially added at 0C to a dichloromethane (2 ml) solution of <strong>[1496-40-8]2-(1-piperidinyl)-5-(trifluoromethyl)aniline</strong> (51.2 mg, 0.209 mmol), obtained as described in Referential Example 1-2. The resulting mixture was warmed to room temperature and stirred for 60 hours. Water was added to the mixture, and the resulting mixture was extracted three times with ethyl acetate. The obtained organic layer was washed with a saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (30 g, hexane/ethyl acetate = 8/1-6/1). Thus, N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]-4-nitrobenzamide (GIF-0345) (46.3 mg, 56.3%) was yielded as a yellow solid. The melting point, and results of TLC and 1H NMR (CDCl3, 400 MHz), are as follows: m.p. 125-136C; TLC Rf 0.33 (hexane/ethyl acetate = 4/1); 1H NMR (CDCl3, 400 MHz) delta 1.62-1.70 (m, 2H, CH2), 1.77 (tt, 4H, J = 5.0, 5.0 Hz, 2CH2), 2.88 (t, 4H, J = 5.0 Hz, 2CH2), 7.30 (d, 1H, J = 8.0 Hz, aromatic), 7.40 (dd, 1H, J = 1.6, 8.2 Hz, aromatic), 8.10 (dd, 2H, J = 1.8, 6.8 Hz, aromatic), 8.41 (d, 2H, J = 1.8, 6.8 Hz, aromatic), 8.86 (d, 1H, J = 2.0 Hz, aromatic), 9.54 (s, 1H, NH).

References: [1]Patent: EP1712242,2006,A1 .Location in patent: Page/Page column 37; 38.

23
[ 1496-40-8 ]
[ 100-07-2 ]
N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]-4-methoxybenzamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
100%	With triethylamine; In dichloromethane; at 0 - 20℃; for 17h;	4-Methoxybenzoyl chloride (250 mg, 1.47 mmol, commercially available product) and triethylamine (254 mul, 1.83 mmol) were sequentially added at 0C to a dichloromethane (4 ml) solution of <strong>[1496-40-8]2-(1-piperidinyl)-5-(trifluoromethyl)aniline</strong> (147 mg, 0.602 mmol), obtained as described in Referential Example 1-2. The resulting mixture was warmed to room temperature and stirred for 17 hours. Water was added to the mixture, and the resulting mixture was extracted three times with ethyl acetate. The obtained organic layer was washed with a saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (20 g, hexane/ethyl acetate = 5/1). Thus, N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]-4-methoxybenzamide (GIF-0615) (240 mg, quant.) was yielded as a colorless solid. The melting point, and results of TLC and 1H NMR (CDCl3, 400 MHz), are as follows: m.p. 111-114C; TLC Rf 0.33 (hexane/ethyl acetate = 4/1); 1H NMR (CDCl3, 400 MHz) delta 1.64-1.68 (m, 2H, CH2), 1.78 (tt, 4H, J = 5.4, 5.4 Hz, 2CH2), 1.60-1.70 (m, 2H, CH2), 2.39-2.41 (m, 2H, CH2), 2.87 (t, 4H, J = 5.4 Hz, 2CH2), 3.89 (s, 3H, CH3), 7.03 (dd, 2H, J = 2.0, 7.0 Hz, aromatic), 7.23 (d, 1H, J = 8.0 Hz, aromatic), 7.32 (dd, 1H, J = 1.6, 8.0 Hz, aromatic), 7.91 (dd, 2H, J = 2.0, 7.0 Hz, aromatic), 8.88 (d, 1H, J = 1.6 Hz, aromatic), 9.34 (s, 1H, NH).

References: [1]Patent: EP1712242,2006,A1 .Location in patent: Page/Page column 38.

24
[ 1496-40-8 ]
[ 98-59-9 ]
N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]-para-toluenesulfonamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
100%	With triethylamine; In dichloromethane; at 20℃; for 60h;	p-Toluenesulfonyl chloride (233 g, 1.22 mmol, commercially available product) and triethylamine (254 mul, 1.83 mmol) were sequentially added at room temperature to a dichloromethane (5 ml) solution of <strong>[1496-40-8]2-(1-piperidinyl)-5-(trifluoromethyl)aniline</strong> (149 mg, 0.610 mmol), obtained as described in Referential Example 1-2. The resulting mixture was stirred for 60 hours. Water was added to the mixture, and the resulting mixture was extracted three times with ethyl acetate. The obtained organic layer was washed with a saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (20 g, hexane/ethyl acetate = 10/1). Thus, N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]-p-toluenesulfonamide (GIF-0622) (243 mg, quant) was yielded as a colorless solid. The melting point, and results of TLC and 1H NMR (CDCl3, 400 MHz), are as follows: m.p. 117-134C; TLC Rf 0.49 (hexane/ethyl acetate = 5/1); 1H NMR (CDCl3, 400 MHz) delta 1.55-1.60 (m, 2H, CH2), 1.66 (tt, 4H, J = 5.2, 5.2 Hz, 2CH2), 2.36 (s, 3H, CH3), 2.51 (t, 4H, J = 5.2 Hz, 2CH2), 7.11 (d, 1H, J = 8.0 Hz, aromatic), 7.22-7.28 (m, 3H, aromatic), 7.71 (dd, 2H, J = 1.8, 8.6 Hz, aromatic), 7.85 (d, 1H, J = 2.0 Hz, aromatic), 7.94 (s, 1H, NH).

References: [1]Patent: EP1712242,2006,A1 .Location in patent: Page/Page column 38; 39.

25
[ 1496-40-8 ]
[ 98-88-4 ]
N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)benzamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
88%	With triethylamine; In dichloromethane; at 0 - 20℃; for 3h;	General procedure: A 25 mL round bottom flask initiallyplaced in an ice bath was charged with 0.629 g (3.389 mmol) ofisonicotinoyl chloride hydrochloride, 0.800 mL of triethylamine,8.00 mL of dichoromethane and 0.400 (1.64 mmol) of 2-(piperidin-1-yl)-5-(trifluoromethyl) aniline (8). The ice-bathwas removed andthe mixture was magnetically stirred at room temperature for 3 h.Then, 10.0 mL of distilled water was added, and the mixture wastransferred to a separatory funnel. The aqueous layer was extractedwith ethyl acetate (4 x 30.0 mL). The organic extracts were combinedand the resulting organic layer was washed with brine, driedover sodium sulphate, filtered, and concentrated under reducedpressure. The residue was purified by silica gel column chromatographyeluted with hexane-ethyl acetate (3:1 v/v). The solid wasfurther recrystallized with acetone. The compound SRPIN340 wasobtained as a white solid in 75% yield (430 mg, 1.23 mmol).
86.7%	With triethylamine; In dichloromethane; at 0 - 20℃; for 18h;	Benzoyl chloride (50.0 mul, 0.430 mmol, commercially available product) and triethylamine (170 mul, 1.21 mmol) were sequentially added at 0C to a dichloromethane (3 ml) solution of <strong>[1496-40-8]2-(1-piperidinyl)-5-(trifluoromethyl)aniline</strong> (102 mg, 0.417 mmol), obtained as described in Referential Example 1-2. The resulting mixture was warmed to room temperature and stirred for 18 hours. Water was added to the mixture, and the resulting mixture was extracted three times with ethyl acetate. The obtained organic layer was washed with a saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (20 g, hexane/ethyl acetate = 10/1). Thus, N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]benzamide (GIF-0344) (126 mg, 86.7%) was yielded as a colorless solid. The melting point, and results of TLC and 1H NMR (CDCl3, 400 MHz), are as follows: m.p. 128-129C; TLC Rf 0.46 (hexane/ethyl acetate = 4/1); 1H NMR (CDCl3, 400 MHz) delta 1.62-1.70 (m, 2H, CH2), 1.78 (tt, 4H, J = 5.2, 5.2 Hz, 2CH2), 2.88 (t, 4H, J = 5.2 Hz, 2CH2), 7.26 (d, 1H, J = 8.6 Hz, aromatic), 7.35 (d, 1H, J = 0.8, 8.6 Hz, aromatic), 7.52-7.61 (m, 1H, aromatic), 8.10 (m, 2H, aromatic), 7.94 (m, 2H, aromatic), 8.91 (d, 1H, J = 0.8 Hz, aromatic), 9.44 (s, 1H, NH).

References: [1]European Journal of Medicinal Chemistry,2017,vol. 134,p. 97 - 109.
[2]Patent: EP1712242,2006,A1 .Location in patent: Page/Page column 37.

26
[ 1496-40-8 ]
[ 39178-35-3 ]
[ 218156-96-8 ]

Yield	Reaction Conditions	Operation in experiment
86.3%	With triethylamine; In dichloromethane; at 0℃; for 0.5h;Product distribution / selectivity;	Isonicotinoyl chloride hydrochloride (6.48 g, 36.4 mmol, commercially available product) and triethylamine (5.57 ml, 54.6 mmol) were sequentially added at 0C to a dichloromethane (10 ml) solution of <strong>[1496-40-8]2-(1-piperidinyl)-5-(trifluoromethyl)aniline</strong> (4.45 g, 18.2 mmol) obtained as described in Referential Example 1-2B. The mixture was stirred for half an hour. Water was added to the mixture, and the resulting mixture was extracted three times with ethyl acetate. The obtained organic layer was washed with a saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (200 g, hexane/ethyl acetate = 1/1) and recrystallization. Thus, N-[2-(1-piperidinyl)-5-(trifluoromethyl) phenyl]isonicotinamide (SRPIN-1, GIF-0340) (5.49 g, 86.3%) was yielded as a colorless solid.
75%	With triethylamine; In dichloromethane; at 0 - 20℃; for 3h;	A 25 mL round bottom flask initiallyplaced in an ice bath was charged with 0.629 g (3.389 mmol) ofisonicotinoyl chloride hydrochloride, 0.800 mL of triethylamine,8.00 mL of dichoromethane and 0.400 (1.64 mmol) of 2-(piperidin-1-yl)-5-(trifluoromethyl) aniline (8). The ice-bathwas removed andthe mixture was magnetically stirred at room temperature for 3 h.Then, 10.0 mL of distilled water was added, and the mixture wastransferred to a separatory funnel. The aqueous layer was extractedwith ethyl acetate (4 x 30.0 mL). The organic extracts were combinedand the resulting organic layer was washed with brine, driedover sodium sulphate, filtered, and concentrated under reducedpressure. The residue was purified by silica gel column chromatographyeluted with hexane-ethyl acetate (3:1 v/v). The solid wasfurther recrystallized with acetone. The compound SRPIN340 wasobtained as a white solid in 75% yield (430 mg, 1.23 mmol).TLC Rf = 0.13 (hexane - ethyl acetate 3:1 v/v). mp 95.6-96.7 C.IR (ATR, cm-1) numax: 3347, 2945, 2917, 2811, 1679, 1611, 1587, 1556,1527, 1455, 1434, 1380, 1334, 1308, 1239, 1165, 1107, 1093, 1061,1022, 915, 895, 878, 839, 826, 751, 728, 681, 662, 644. 1H NMR(300 MHz, CDCl3) delta: 1.65-1.81 (m, 6H), 2.86 (t, 4H, J = 5.1 Hz), 7.28(d, 1H, J = 8.4 Hz), 7.37 (dd, 1H, J = 8.4 Hz and J = 1.8 Hz), 7.76 (dd,2H, J = 4.5 Hz and J = 1.5 Hz), 8.83-8.85 (m, 3H), 9.55 (s, 1H, NH).13C NMR (75 MHz, CDCl3) delta: 24.0, 27.1, 53.8, 116.6, 120.8, 121.1, 121.6(q, J C-F =3.7 Hz), 124.2 (q, J C-F = 270.5 Hz), 127.5 (q, J C-F = 32.3 Hz),133.4, 141.8, 145.9, 151.1, 163.0. HRMS (M + H+): Calculated forC18H19F3N3O, 350.1480; found: 350.1420.
33.9%	With dmap; triethylamine; In dichloromethane; at 0 - 20℃; for 19.5h;Product distribution / selectivity;	Isonicotinoyl chloride hydrochloride (151 mg, 0.850 mmol, commercially available product), triethylamine (450 mul, 3.23 mmol), and a catalytic amount of 4-(dimethylamino)pyridine were sequentially added at 0C to a dichloromethane (5 ml) solution of <strong>[1496-40-8]2-(1-piperidinyl)-5-(trifluoromethyl)aniline</strong> (173 mg, 0.708 mmol), obtained as described in Referential Example 1-2A. The resulting mixture was warmed to room temperature and stirred for 19.5 hours. Water was added to the mixture, and the resulting mixture was extracted three times with ethyl acetate. The obtained organic layer was washed with a saturated aqueous solution of sodium bicarbonate, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (10 g, hexane/ethyl acetate = 1.5/1) and recrystallization (hexane). Thus, N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]isonicotinamide (SRPIN-1, code name GIF-0340) (83.8 mg, 0.240 mmol, 33.9%) was yielded as a colorless solid. The melting point, and results of TLC and 1H NMR (CDCl3, 400 MHz), are as follows: m.p. 96-98C; TLC Rf 0.40 (hexane/ethyl acetate = 1/1); 1H NMR (CDCl3, 400 MHz) delta 1.67-1.68 (m, 2H, CH2), 1.78 (tt, 4H, J = 5.5, 5.5 Hz, 2CH2), 2.88 (t, 4H, J = 5.5 Hz, 2CH2), 7.29 (d, 1H, J = 8.2 Hz, aromatic), 7.40 (dd, 1H, J = 1.8, 8.2 Hz, aromatic), 7.76 (dd, 2H, J = 2.0, 4.4 Hz, aromatic), 8.86 (dd, 2H, J = 2.0, 4.4 Hz, aromatic), 8.87 (d, 1H, J = 1.8 Hz, aromatic), 9.53 (s, 1H, NH).

With triethylamine; In dichloromethane; water;

[Reference example 1-3B] Isonicotinoyl chloride hydrochloride (6.48 g, 36.4 mmol; commercial product) and triethylamine (5.57 mL, 54.6 mmol) were added sequentially at 0C to a dichloromethane (10 mL) solution of [1496-40-8]2-(1-piperidinyl)-5-(trifluoromethyl)aniline (4.45 g, 18.2 mmol) obtained in Reference example 1-2B. The mixture was stirred for 0.5 hours. Water was added to the mixture and then the mixture was subjected to extraction with ethyl acetate (x3). The thus obtained organic layer was washed with saturated sodium chloride solution, dried using anhydrous sodium sulfate, filtered, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (200 g, hexane/ethyl acetate = 1/1) and recrystallization (hexane), so that N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]isonicotinamide (Compound 1) (5.49 g, 86.3%) was obtained as colorless solid.

References: [1]Patent: EP1712242,2006,A1 .Location in patent: Page/Page column 18; 31.
[2]European Journal of Medicinal Chemistry,2017,vol. 134,p. 97 - 109.
[3]Patent: EP1712242,2006,A1 .Location in patent: Page/Page column 18; 30; 31.
[4]Patent: EP2279750,2011,A1 .

27
[ 1496-40-8 ]
[ 20260-53-1 ]
N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)nicotinamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
65%	With triethylamine; In dichloromethane; at 0 - 20℃; for 3h;	General procedure: A 25 mL round bottom flask initiallyplaced in an ice bath was charged with 0.629 g (3.389 mmol) ofisonicotinoyl chloride hydrochloride, 0.800 mL of triethylamine,8.00 mL of dichoromethane and 0.400 (1.64 mmol) of 2-(piperidin-1-yl)-5-(trifluoromethyl) aniline (8). The ice-bathwas removed andthe mixture was magnetically stirred at room temperature for 3 h.Then, 10.0 mL of distilled water was added, and the mixture wastransferred to a separatory funnel. The aqueous layer was extractedwith ethyl acetate (4 x 30.0 mL). The organic extracts were combinedand the resulting organic layer was washed with brine, driedover sodium sulphate, filtered, and concentrated under reducedpressure. The residue was purified by silica gel column chromatographyeluted with hexane-ethyl acetate (3:1 v/v). The solid wasfurther recrystallized with acetone. The compound SRPIN340 wasobtained as a white solid in 75% yield (430 mg, 1.23 mmol).
45.3%	With triethylamine; In dichloromethane; at 0 - 20℃; for 16.5h;	Nicotinoyl chloride hydrochloride (122 mg, 0.685 mmol, commercially available product) and triethylamine (250 mul, 1.79 mmol) were sequentially added at 0C to a dichloromethane (5 ml) solution of <strong>[1496-40-8]2-(1-piperidinyl)-5-(trifluoromethyl)aniline</strong> (152 mg, 0.622 mmol), obtained as described in Referential Example 1-2. The resulting mixture was warmed to room temperature and stirred for 16.5 hours. Water was added to the mixture, and the resulting mixture was extracted three times with ethyl acetate. The obtained organic layer was washed with a saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (15 g, hexane/ethyl acetate = 1.5/1-1/1). Thus, N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]nicotinamide (GIF-0343) (98.4 mg, 45.3%) was yielded as a colorless solid. The melting point, and results of TLC and 1H NMR (CDCl3, 400 MHz), are as follows: m.p. 145-146C; TLC Rf 0.40 (hexane/ethyl acetate = 1/1); 1H NMR (CDCl3, 400 MHz) delta 1.62-1.69 (m, 2H, CH2), 1.79 (tt, 4H, J = 5.8, 5.8 Hz, 2CH2), 2.88 (t, 4H, J = 5.8 Hz, 2CH2), 7.29 (d, 1H, J = 8.4 Hz, aromatic), 7.39 (dd, 1H, J = 2.0, 8.4 Hz, aromatic), 7.51 (dd, 1H, J = 4.8, 8.0 Hz, aromatic), 8.30 (ddd, 1H, J = 1.6, 2.4, 8.0 Hz, aromatic), 8.82 (dd, 1H, J = 1.6, 4.8 Hz, aromatic), 8.87 (d, 1 H, J = 2.0 Hz, aromatic), 9.16 (d, 1 H, J = 2.4 Hz, aromatic), 9.53 (s, 1 H, NH).

References: [1]European Journal of Medicinal Chemistry,2017,vol. 134,p. 97 - 109.
[2]Patent: EP1712242,2006,A1 .Location in patent: Page/Page column 36.

28
[ 1496-40-8 ]
[ 20260-53-1 ]
1-nicotinoyl-3-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]thiourea [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
93.7%		An acetonitrile (15 ml) solution containing potassium thiocyanate (119 mg, 1.22 mmol, commercially available product) and nicotinoyl chloride hydrochloride (352 mg, 1.97 mmol, commercially available product) was stirred at 70C for 40 minutes. The mixture was cooled to room temperature, and then an acetonitrile (5 ml) solution of <strong>[1496-40-8]2-(1-piperidinyl)-5-(trifluoromethyl)aniline</strong> (244 mg, 1.00 mmol), obtained as described in Referential Example 1-2, and triethylamine (278 mul, 2.00 mmol) were sequentially added thereto. The resulting mixture was stirred at 50C for one hour. Water was added to the mixture, and the resulting mixture was extracted three times with dichloromethane. The obtained organic layer was washed with a saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (25 g, hexane/ethyl acetate = 4/1-1/1). Thus, 1-nicotinoyl-3-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]thiourea (GIF-0624) (383 mg, 93.7%) was yielded as a pale yellow solid. The melting point, and results of TLC and 1H NMR (CD3OD, 400 MHz), are as follows: m.p. 142-144C; TLC Rf 0.26 (hexane/ethyl acetate = 1/1); 1H NMR (CDCl3, 400 MHz) delta 1.58-1.67 (m, 2H, CH2), 1.75-1.85 (m, 4H, 2CH2), 2.89-2.95 (m, 4H, 2CH2), 7.33-7.40 (m, 1H, aromatic), 7.44-7.48 (m, 1H, aromatic), 7.60-7.65 (m, 1H, aromatic), 8.76-8.78 (m, 1H, aromatic), 9.05 (s, 0.6H, aromatic), 9.09-9.14 (m, 1H, aromatic), 8.37-8.39 (m, 1H, aromatic), 8.49 (s, 0.4H, aromatic).
	With triethylamine; In acetonitrile;	[Reference example 3] Synthesis of Compound 3 An acetonitrile (15 mL) solution of potassium thiocyanate (commercial product) (198 mg, 2.04 mmol) and nicotinoyl chloride hydrochloride (272 mg, 1.53 mmol; commercial product) was stirred at 80C for 1 hour. The mixture was left to room temperature. 2-(1-Piperidinyl)-5-(trifluoromethyl)aniline (250 mg, 1.02 mmol) obtained in Reference example 1-2 and triethylamine (285 muL, 2.04 mmol) were added sequentially to the mixture. The mixture was stirred at 50C for 1 hour. The mixture was poured into an aqueous saturated sodium bicarbonate solution and then the mixture was subjected to extraction with dichloromethane (x3). The thus obtained organic layer was washed with water, dried using anhydrous sodium sulfate, filtered, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (30 g, hexane/ethyl acetate/dichloromethane = 6/3/4), so that 1-nicotinoyl-3-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]thiourea (Compound 3) (70.7 mg, 30.1%) was obtained as light yellow solid. The results of the melting point, TLC, 1H NMR (CD3OD, 400 MHz), and IR are as follows. Melting point 155-156C; TLC Rf 0.21 (hexane/ethyl acetate /dichloromethane =4/3/3); 1H NMR (CDCl3, 300 MHz) delta1.61 (m, 2H, J = 5.3 Hz, CH2), 1.81 (m, 4H, J = 5.3 Hz, 2CH2), 2.89 (t, 4H, J = 5.3 Hz, 2CH2), 7.24 (d, 1H, J = 8.4 Hz, aromatic), 7.47 (dd, 1H, J = 2.4, 8.4 Hz, aromatic), 7.52 (dd, 1H, J = 4.8, 8.0 Hz, aromatic), 8.23 (ddd, 1H, J = 1.7, 1.7, 8.0 Hz, aromatic), 8.89 (dd, 1H, J = 1.7, 4.8 Hz, aromatic), 9.09 (br s, 2H, aromatic, NH), 9.18 (d, 1H, J = 2.4 Hz, aromatic), 12.9 (br s, 1H, NH); IR (KBr, cm-1) 644, 704, 731, 804, 826, 883, 908, 1026, 1078, 1123, 1165, 1204, 1221, 1271, 1298,1335,1439,1479,1531,1587,1614,1678,2814,2855,2940.

References: [1]Patent: EP1712242,2006,A1 .Location in patent: Page/Page column 39.
[2]Patent: EP2279750,2011,A1 .

29
C₃₁H₄₇N₄O₁₂P [ No CAS ]
[ 1496-40-8 ]
C₃₉H₅₇F₃N₅O₉P [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In dichloromethane; at 65℃; for 1h;Microwave;	Alcohol (200mg, 0.36 mmol) was taken up in THF (5mL). NaH (43mg,1.08 mmol), and disuccinimidecarbonyl (276mg, 1.08 mmol) were added. Thereaction was refluxed for 6h until complete via LC/MS analysis. Ethyl acetateand 1M HC1 were added. The organic layer was separated and washed withbrine, dried, and concentrated. The residue was then taken up in DCM (ImL)and the aniline (175mg, 0.72 mmol) was added. The mixture was heated inthe microwave at 65C for Ih. The reaction was then concentrated andpurified via flash chromatography to provide the desired carbamate (30mg).This diethylphosphonate was then taken up in acetonitrile (ImL) and 2,6-lutidine (11.6mg, 0.11 mmol) was added. The mixture was cooled to 0C andthen TMSI (22mg, 0.11 mmol) was added. The reaction was warmed to roomtemp and stirred for 2h. The reaction was then quenched with triethylamine,then methanol and concentrated. The residue was purified via HPLC(acetonitrile:water) to provide the desired diacid 85 (1.6mg).lH NMR(300MHz, CDsOD) b 1.05 (m, 12H), 1.35-1.83 (m, 19H), 2.11 (m, 1H), 2.32 (m/1H), 2.48 (m, 1H), 2.89 (m, 2H), 3.95 (m, 1H), 4.38 (m, 1H), 4.53 (m, 1H), 5.08(m, 1H), 5.25 (m, 1H), 5.41 (m, 1H), 5.98 (m, 1H), 7.37 (s, 2H), 8.23 (s, 1H). 31PNMR (300MHz) 5 20.08. LC/MS: 772 (M+l).

References: [1]Patent: WO2006/20276,2006,A2 .Location in patent: Page/Page column 321-322.

30
[ 1496-40-8 ]
[ 1191932-26-9 ]
[ 1191932-43-0 ]

Yield	Reaction Conditions	Operation in experiment
27%	With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In N,N-dimethyl-formamide; at 60℃; for 3h;	Reference Example 41 2-Amino-8-bromo-7-methoxy-6-[2-methyl-5-N-(2-piperidino-5-trifluoromethylphenyl)carbamoylphenyl]q uinazoline (Compound A41) Compound A18 (1.94 g, 5.00 mmol) was dissolved in DMF (10 mL), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (2.88 g, 15.0 mmol), 4-dimethylaminopyridine (0.915 g, 7.50 mmol) and <strong>[1496-40-8]2-piperidino-5-trifluoromethylaniline</strong> () (1.46 g, 6.00 mmol) were added thereto, followed by stirring at 60C for 3 hours. To the reaction mixture was added saturated aqueous sodium bicarbonate, followed by extraction with ethyl acetate/isopropanol (5/1), and the organic layer was washed with saturated brine, followed by drying over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate) to obtain Compound A41(0.840 g, 27%). 1H NMR (300 MHz, DMSO-d6) delta (ppm) 1.44-1.56 (m, 2H), 1.57-1.69 (m, 4H), 2.25 (s, 3H), 2.82-2.91 (m, 4H), 3.44 (s, 3H), 7.28 (br s, 2H), 7.39 (d, J J = 8.4 Hz, 1H), 7.49 (d, J = 8.4 Hz, 1H), 7.58 (d, J = 8.1 Hz, 1H), 7.78 (s, 1H), 7.90 (s, 1H), 7.94 (d, J = 8.1 Hz, 1H), 8.42 (s, 1H), 9.09 (s, 1H), 9.68 (s, 1H). ESI m/z (M+H)+ 614.

References: [1]Patent: EP2269993,2011,A1 .Location in patent: Page/Page column 59.

31
[ 110-89-4 ]
[ 1496-40-8 ]

References: [1]European Journal of Medicinal Chemistry,2017,vol. 134,p. 97 - 109.
[2]Journal of Medicinal Chemistry,2020,vol. 63,p. 103 - 121.

32
[ 49609-84-9 ]
[ 1496-40-8 ]
2-chloro-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)nicotinamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
78%	With triethylamine; In dichloromethane; at 0 - 20℃; for 3h;	General procedure: A 25 mL round bottom flask initiallyplaced in an ice bath was charged with 0.629 g (3.389 mmol) ofisonicotinoyl chloride hydrochloride, 0.800 mL of triethylamine,8.00 mL of dichoromethane and 0.400 (1.64 mmol) of 2-(piperidin-1-yl)-5-(trifluoromethyl) aniline (8). The ice-bathwas removed andthe mixture was magnetically stirred at room temperature for 3 h.Then, 10.0 mL of distilled water was added, and the mixture wastransferred to a separatory funnel. The aqueous layer was extractedwith ethyl acetate (4 x 30.0 mL). The organic extracts were combinedand the resulting organic layer was washed with brine, driedover sodium sulphate, filtered, and concentrated under reducedpressure. The residue was purified by silica gel column chromatographyeluted with hexane-ethyl acetate (3:1 v/v). The solid wasfurther recrystallized with acetone. The compound SRPIN340 wasobtained as a white solid in 75% yield (430 mg, 1.23 mmol).

References: [1]European Journal of Medicinal Chemistry,2017,vol. 134,p. 97 - 109.

33
[ 1496-40-8 ]
[ 100-51-6 ]
N-(1,2-diphenylethyl)-2-( piperidin-1-yl)-5-(trifluoromethyl)aniline [ No CAS ]

References: [1]Green Chemistry,2018,vol. 20,p. 1297 - 1305.

34
[ 1496-40-8 ]
4-methoxy-3-(N-methyl-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)-phenyl)sulfamoyl)benzoic acid [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2020,vol. 63,p. 103 - 121.

35
[ 1496-40-8 ]
4-methoxy-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2020,vol. 63,p. 103 - 121.

Historical Records

Technical Information

• Alkyl Halide Occurrence • Buchwald-Hartwig C-N Bond and C-O Bond Formation Reactions • Chan-Lam Coupling Reaction • Hydride Reductions • Leuckart-Wallach Reaction • Mannich Reaction • Petasis Reaction • Preparation of Amines • Reactions of Amines • Reactions of Benzene and Substituted Benzenes • Specialized Acylation Reagents-Vilsmeier Reagent • Ugi Reaction

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

{[proInfo.proName]}

CAS No.: 1496-40-8

{[proInfo.proName]}

CAS No.: 1496-40-8

Alternative Products

Product Details of [ 1496-40-8 ]

Safety of [ 1496-40-8 ]

Application In Synthesis of [ 1496-40-8 ]

[ 1496-40-8 ] Synthesis Path-Downstream 1~35

Related Products

Historical Records

Technical Information

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator